Non-genomic actions of estradiol and 4-OH-tamoxifen on murine breast cancer cells

Oncology Reports

Volumn 33, Issue 1, 2015, Pages 439-447

  Raffo, Diego ^a   Pontiggia, Osvaldo ^a   De Kier Joffé, Elisa Bal ^a   Simian, Marina ^a  

^a Instituto de Oncologia Angel H Roffo   (Argentina)

Author keywords

Breast cancer; Estradiol; Non genomic signaling; Tamoxifen

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; AFIMOXIFENE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ILOMASTAT; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; WORTMANNIN; EGFR PROTEIN, HUMAN; EGFR PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE; QUINAZOLINE DERIVATIVE; TAMOXIFEN; TYRPHOSTIN;

ANIMAL CELL; ARTICLE; BREAST CANCER CELL LINE; CANCER HORMONE THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LM05 E CELL LINE; MCF 7 CELL LINE; MOUSE; MURINAE; NONHUMAN; PHARMACOLOGICAL PROCEDURES; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MCF-7 CELLS; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TAMOXIFEN; TYRPHOSTINS;

EID: 84916228350     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3558     Document Type: Article

References (22)

1. Russo J and Russo IH: The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 102: 89-96, 2006.
2. Harvey JM, Clark GM, Osborne CK and Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligandbinding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481, 1999.
3. Graham JD, Yeates C, Balleine RL, et al: Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res 55: 5063-5068, 1995.
4. Sengupta S and Jordan VC: Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Adv Exp Med Biol 630: 206-219, 2008.
5. Musgrove EA and Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9: 631-643, 2009.
6. Levin ER and Pietras RJ: Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat 108: 351-361, 2008.
7. Pietras RJ and Szego CM: Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 265: 69-72, 1977.
8. Pedram A, Razandi M and Levin ER: Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 20: 1996-2009, 2006.
9. Toran-Allerand CD, Guan X, MacLusky NJ, et al: ER-X: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J Neurosci 22: 8391-8401, 2002.
10. Song RX, Fan P, Yue W, Chen Y and Santen RJ: Role of receptor complexes in the extranuclear actions of estrogen receptor α in breast cancer. Endocr Relat Cancer 13 (Suppl 1): S3-S13, 2006.
11. Razandi M, Pedram A, Park ST and Levin ER: Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 278: 2701-2712, 2003.
12. Zheng A, Kallio A and Harkonen P: Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. Endocrinology 148: 2764-2777, 2007.
13. Simian M, Manzur T, Rodriguez V, de Kier Joffe EB and Klein S: A spontaneous estrogen-dependent, tamoxifen-sensitive mouse mammary tumor: a new model system to study hormoneresponsiveness in immune competent mice. Breast Cancer Res Treat 113: 1-8, 2009.
14. Pontiggia O, Rodriguez V, Fabris V, et al: Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions. Breast Cancer Res Treat 116: 247-255, 2009.
15. Pontiggia O, Sampayo R, Raffo D, et al: The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through β1 integrin. Breast Cancer Res Treat 133: 459-471, 2012.
16. V allejo G, Ballare C, Baranao JL, Beato M and Saragueta P: Progestin activation of nongenomic pathways via cross talk of progesterone receptor with estrogen receptor β induces proliferation of endometrial stromal cells. Mol Endocrinol 19: 3023-3037, 2005.
17. Ferlini C, Scambia G, Marone M, et al: Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br J Cancer 79: 257-263, 1999.
18. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, et al: Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 404: 15-21, 2007.
19. Stice JP, Mbai FN, Chen L and Knowlton AA: Rapid activation of nuclear factor κB by 17β-estradiol and selective estrogen receptor modulators: pathways mediating cellular protection. Shock 38: 128-136, 2012.
20. McDonald GT, Sullivan R, Pare GC and Graham CH: Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression. Exp Cell Res 316: 3197-3206, 2010.
21. Grovdal LM, Kim J, Holst MR, Knudsen SL, Grandal MV and van Deurs B: EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Cell Signal 24: 296-301, 2012.
22. Hirata A, Hosoi F, Miyagawa M, et al: HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/ HER3 heterodimer formation in lung cancer cells. Cancer Res 65: 4253-4260, 2005.